JP2003515559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003515559A5 JP2003515559A5 JP2001541504A JP2001541504A JP2003515559A5 JP 2003515559 A5 JP2003515559 A5 JP 2003515559A5 JP 2001541504 A JP2001541504 A JP 2001541504A JP 2001541504 A JP2001541504 A JP 2001541504A JP 2003515559 A5 JP2003515559 A5 JP 2003515559A5
- Authority
- JP
- Japan
- Prior art keywords
- zolmitriptan
- migraine
- vasoconstriction
- vascular bed
- carotid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 3
- 229960001360 zolmitriptan Drugs 0.000 description 3
- 102000035038 5-HT1 receptors Human genes 0.000 description 2
- 108091005478 5-HT1 receptors Proteins 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- -1 dimethylcarbamoyl Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9928578.5A GB9928578D0 (en) | 1999-12-03 | 1999-12-03 | Pharmaceutical formulations |
| GB9928578.5 | 1999-12-03 | ||
| PCT/GB2000/004528 WO2001039772A1 (en) | 1999-12-03 | 2000-11-28 | Pharmaceutical formulations containing zolmitriptan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003515559A JP2003515559A (ja) | 2003-05-07 |
| JP2003515559A5 true JP2003515559A5 (enExample) | 2008-01-10 |
Family
ID=10865629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541504A Pending JP2003515559A (ja) | 1999-12-03 | 2000-11-28 | ゾルミトリプタン含有医薬製剤 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6750237B1 (enExample) |
| EP (1) | EP1237551B1 (enExample) |
| JP (1) | JP2003515559A (enExample) |
| KR (1) | KR100670092B1 (enExample) |
| CN (1) | CN1222287C (enExample) |
| AT (1) | ATE291914T1 (enExample) |
| AU (1) | AU778092B2 (enExample) |
| BR (1) | BRPI0016138B8 (enExample) |
| CA (1) | CA2392050C (enExample) |
| CZ (1) | CZ301528B6 (enExample) |
| DE (1) | DE60019162T2 (enExample) |
| EE (1) | EE05305B1 (enExample) |
| ES (1) | ES2236001T3 (enExample) |
| GB (2) | GB9928578D0 (enExample) |
| HK (2) | HK1048445B (enExample) |
| HU (1) | HU229458B1 (enExample) |
| IL (2) | IL149578A0 (enExample) |
| IS (1) | IS2135B (enExample) |
| MX (1) | MXPA02005319A (enExample) |
| NO (1) | NO322119B1 (enExample) |
| NZ (1) | NZ518862A (enExample) |
| PL (1) | PL200679B1 (enExample) |
| PT (1) | PT1237551E (enExample) |
| RU (1) | RU2255736C2 (enExample) |
| SK (1) | SK287228B6 (enExample) |
| UA (1) | UA75059C2 (enExample) |
| WO (1) | WO2001039772A1 (enExample) |
| ZA (1) | ZA200203704B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
| SE0102855D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
| WO2005115360A2 (en) * | 2004-05-11 | 2005-12-08 | Becton, Dickinson And Company | Formulations of anti-pain agents and methods of using the same |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| EP3216445A1 (en) * | 2004-05-28 | 2017-09-13 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| EP1812428A2 (en) * | 2004-11-19 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Zolmitriptan crystal forms |
| CN100341504C (zh) * | 2004-12-01 | 2007-10-10 | 鲁南制药集团股份有限公司 | 佐米曲普坦速释制剂 |
| EP3263117A1 (en) * | 2005-11-28 | 2018-01-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| WO2008016678A2 (en) * | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| DE602007013440D1 (de) * | 2006-10-19 | 2011-05-05 | Auspex Pharmaceuticals Inc | Substituierte indole |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| US9186359B2 (en) | 2010-10-15 | 2015-11-17 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| JP6121734B2 (ja) * | 2012-02-09 | 2017-04-26 | 久光製薬株式会社 | マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス |
| PT2838517T (pt) | 2012-04-18 | 2018-01-04 | Contera Pharma Aps | Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| KR101624049B1 (ko) | 2014-10-29 | 2016-05-24 | 연세대학교 산학협력단 | 사카린을 이용한 용해도를 증가시킨 약제학적 조성물 |
| CN108135916B (zh) * | 2015-06-19 | 2022-01-28 | 北京科辉智药生物科技有限责任公司 | 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用 |
| WO2017122161A1 (en) | 2016-01-15 | 2017-07-20 | Cadila Healthcare Limited | An intranasal composition comprising 5ht1b/1d receptor agonists |
| JP7227896B2 (ja) | 2016-07-11 | 2023-02-22 | コンテラ ファーマ エー／エス | 朝の無動状態を治療するための拍動性薬物送達系 |
| WO2019126766A1 (en) * | 2017-12-21 | 2019-06-27 | Taiwan Liposome Co., Ltd. | Sustained-release triptan compositions and method of use the same through subdermal route or the like |
| US20210322343A1 (en) | 2020-04-15 | 2021-10-21 | Farzana Shaheen | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69132691T2 (de) | 1990-06-07 | 2002-06-20 | Astrazeneca Ab, Soedertaelje | Indolderivate als 5-HT1-like Agonisten |
| GB9012672D0 (en) * | 1990-06-07 | 1990-08-01 | Wellcome Found | Therapeutic heterocyclic compounds |
| GB9516145D0 (en) * | 1995-08-07 | 1995-10-04 | Wellcome Found | Improved chemical synthesis |
| JP2000505090A (ja) * | 1996-07-11 | 2000-04-25 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | インドール選択的セロトニンアゴニストを含む包接錯体 |
| GB2315673A (en) * | 1996-08-01 | 1998-02-11 | Merck & Co Inc | Treatment of migraine |
| AU718967B2 (en) | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
-
1999
- 1999-12-03 GB GBGB9928578.5A patent/GB9928578D0/en not_active Ceased
-
2000
- 2000-11-28 PT PT00979765T patent/PT1237551E/pt unknown
- 2000-11-28 ES ES00979765T patent/ES2236001T3/es not_active Expired - Lifetime
- 2000-11-28 HK HK03100621.4A patent/HK1048445B/en not_active IP Right Cessation
- 2000-11-28 CZ CZ20021901A patent/CZ301528B6/cs not_active IP Right Cessation
- 2000-11-28 JP JP2001541504A patent/JP2003515559A/ja active Pending
- 2000-11-28 SK SK753-2002A patent/SK287228B6/sk not_active IP Right Cessation
- 2000-11-28 CN CNB008163820A patent/CN1222287C/zh not_active Expired - Lifetime
- 2000-11-28 PL PL357597A patent/PL200679B1/pl unknown
- 2000-11-28 WO PCT/GB2000/004528 patent/WO2001039772A1/en not_active Ceased
- 2000-11-28 AU AU17157/01A patent/AU778092B2/en not_active Expired
- 2000-11-28 UA UA2002075443A patent/UA75059C2/uk unknown
- 2000-11-28 US US10/129,773 patent/US6750237B1/en not_active Expired - Lifetime
- 2000-11-28 RU RU2002117649/15A patent/RU2255736C2/ru active
- 2000-11-28 DE DE60019162T patent/DE60019162T2/de not_active Expired - Lifetime
- 2000-11-28 NZ NZ518862A patent/NZ518862A/en not_active IP Right Cessation
- 2000-11-28 BR BRPI0016138A patent/BRPI0016138B8/pt not_active IP Right Cessation
- 2000-11-28 GB GB0214845A patent/GB2373726B/en not_active Expired - Lifetime
- 2000-11-28 AT AT00979765T patent/ATE291914T1/de active
- 2000-11-28 CA CA002392050A patent/CA2392050C/en not_active Expired - Lifetime
- 2000-11-28 EE EEP200200283A patent/EE05305B1/xx unknown
- 2000-11-28 KR KR1020027006849A patent/KR100670092B1/ko not_active Expired - Lifetime
- 2000-11-28 HK HK03100515.3A patent/HK1048442B/zh not_active IP Right Cessation
- 2000-11-28 IL IL14957800A patent/IL149578A0/xx active IP Right Grant
- 2000-11-28 HU HU0203597A patent/HU229458B1/hu unknown
- 2000-11-28 EP EP00979765A patent/EP1237551B1/en not_active Expired - Lifetime
-
2002
- 2002-05-09 ZA ZA200203704A patent/ZA200203704B/xx unknown
- 2002-05-09 IL IL149578A patent/IL149578A/en unknown
- 2002-05-24 IS IS6394A patent/IS2135B/xx unknown
- 2002-05-28 NO NO20022525A patent/NO322119B1/no not_active IP Right Cessation
- 2002-05-29 MX MXPA02005319A patent/MXPA02005319A/es active IP Right Grant
-
2004
- 2004-05-27 US US10/854,959 patent/US7220767B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003515559A5 (enExample) | ||
| RU2006122599A (ru) | Способ изготовления твердого, орально применяемого фармацевтического состава | |
| JP2006502183A5 (enExample) | ||
| AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| JP2006514095A5 (enExample) | ||
| JP2002501025A5 (enExample) | ||
| TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
| JP2002520273A5 (enExample) | ||
| JP2002522485A5 (enExample) | ||
| JP2004517472A5 (enExample) | ||
| FI942395A0 (fi) | Indolijohdannaiset | |
| WO2002053140A3 (en) | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents | |
| BR0107565A (pt) | Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas | |
| JP2002516282A5 (enExample) | ||
| JP2008512527A5 (enExample) | ||
| JP2008531742A5 (enExample) | ||
| EE05305B1 (et) | Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend | |
| JP2004537500A5 (enExample) | ||
| JP2006516141A5 (enExample) | ||
| JP2005527477A5 (enExample) | ||
| UY25825A1 (es) | Procedimiento para preparar derivados de indol | |
| MY137595A (en) | N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer | |
| JP2002114686A5 (enExample) | ||
| JP2003522147A5 (enExample) | ||
| JP2004537546A5 (enExample) |